.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XX62_Ivosidenib.Ivosidenib .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XX62_Ivosidenib.Ivosidenib| name: | Ivosidenib |
| ATC code: | L01XX62 | route: | oral |
| n-compartments | 2 |
Ivosidenib is an orally administered, small-molecule inhibitor of the isocitrate dehydrogenase 1 (IDH1) enzyme. It is approved for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation. It is also used in patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 mutation.
Pharmacokinetic parameters reported in adult patients with advanced malignancies following oral administration of ivosidenib at the recommended dose (FDA label and population PK analysis).
DiNardo, CD, et al., & Kantarjian, HM (2018). Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. The New England journal of medicine 378(25) 2386–2398. DOI:10.1056/NEJMoa1716984 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29860938
Fan, B, et al., & Yang, H (2024). Pharmacokinetics/pharmacodynamics of ivosidenib in advanced IDH1-mutant cholangiocarcinoma: findings from the phase III ClarIDHy study. Cancer chemotherapy and pharmacology 93(5) 471–479. DOI:10.1007/s00280-023-04633-5 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38278871
Jiang, X, et al., & Le, K (2021). Population pharmacokinetic and exposure-response analyses of ivosidenib in patients with IDH1-mutant advanced hematologic malignancies. Clinical and translational science 14(3) 942–953. DOI:10.1111/cts.12959 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33493392